Press Release

NATCO Pharma Ltd

Natco House
Road No.2, Banjara Hills
Hyderabad-500 034, India

Hyderabad, India, February 12th, 2025: Natco Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today announced results for third quarter of financial year 2025.

NATCO records ₹651.1 Crore consolidated revenue and ₹132.4 Crore of profit after tax for Q3 FY25

NATCO recorded consolidated total revenue of ₹651.1 Crore for the third quarter of FY2025 that ended on 31st December 2024, as against ₹795.6 Crore for the same period last year. The net profit for the period, on a consolidated basis, was ₹132.4 Crores as against ₹212.7 Crore same period last year.

During the quarter, contribution from the export formulation business was lower. However, the Company expects healthy growth of business in the ensuing quarters.

The Board of Directors has declared third interim dividend of INR 1.5 per equity share, for FY 2024-25.

Segmental Revenue Split (INR Cr)

Segment	Q3FY25	Q2FY25	Q3FY24
Active Pharmaceutical Ingredients (API)	66.6	49.6	46.3
Domestic Formulations	96.1	102.3	99.4
Formulations export (Incl. profit share and subs)	285.8	1,211.3	605.6
Other operating and non-operating income	187.5	57.6	30.2
Crop Health Sciences (CHS)	15.1	14.1	14.1
Total	**651.1**	**1,434.9**	**795.6**

About NATCO Pharma Limited

NATCO Pharma Limited (www.natcopharma.com), (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company's manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com or click on LinkedIn or X (formerly Twitter)

For further information please contact:

Rajeev Menon, Investor Relations

r.menon@natcopharma.co.in/investors@natcopharma.co.in

Rajesh Chebiyam, EVP - CHS

rajesh.chebiyam@natcopharma.co.in